BMY - Bristol-Myers Squibb Company
Bristol-Myers Squibb Company
345 Park Avenue
New York, NY 10154
United States
212-546-4000
http://www.bms.com
Sector: Healthcare
Industry: Drug Manufacturers - Major
Full Time Employees: 23,700
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Giovanni Caforio | Chairman & CEO | N/A | N/A | 1965 |
| Mr. Charles A. Bancroft | Exec. VP of Global Bus. Operations & CFO | 3.19M | 667.77k | 1960 |
| Dr. Thomas J. Lynch Jr. | Exec. VP of R&D & Chief Scientific Officer | 2.55M | N/A | 1961 |
| Ms. Sandra Leung | Exec. VP & Gen. Counsel | 2.7M | 9.92M | 1961 |
| Mr. Joseph C. Caldarella | Sr. VP, Corp. Controller & Principal Accounting Officer | N/A | N/A | 1956 |
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The company has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; Compugen Ltd.; Infinity Pharmaceuticals, Inc.; and Tsinghua University, as well as a research partnership with Sirenas. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Corporate Governance
Bristol-Myers Squibb Company’s ISS Governance QualityScore as of November 1, 2018 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 5; Compensation: 5.
